Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
X4 Pharmaceuticals
AddedFeb 19, 2024
UpdatedJun 18, 2026
X4 Pharmaceuticals

X4 Pharmaceuticals

Public

X4 Pharmaceuticals: A clinical-stage biopharmaceutical firm specializing in novel therapeutics for rare diseases and cancer.

HQ
Boston, MA, US
Founded
2014
Overview
Compare
Fundraising
Employees
Website

Founded with a mission to develop novel therapeutics for rare diseases and cancer, X4 Pharmaceuticals is a clinical-stage biopharmaceutical company. The company focuses on improving immune cell trafficking through its oral small molecule drug candidates that antagonize the CXCR4 pathway, a crucial component in immune surveillance. Their core vision is to address unmet medical needs in primary immunodeficiencies and oncology, offering innovative treatments that enhance patient outcomes.

X4 Pharmaceuticals has garnered attention from notable investors and industry experts, contributing to its rapid progress in clinical trials. The company's key achievements include the approval of its lead drug candidate in the U.S., marking a significant milestone in their mission to treat rare diseases. With a strong pipeline and impactful research, X4 Pharmaceuticals continues to make strides in the biopharmaceutical landscape, aiming to transform the lives of patients with severe and rare conditions.

X4 Pharmaceuticals - Quick Facts

When was X4 Pharmaceuticals founded?

X4 Pharmaceuticals was founded in 2014.

Where is X4 Pharmaceuticals' headquarters located?

X4 Pharmaceuticals' headquarters is located in Boston, MA, US.

When was X4 Pharmaceuticals' last funding round?

X4 Pharmaceuticals' most recent funding round was for $115M (USD) in August 2023.

How much has X4 Pharmaceuticals raised to-date?

As of Aug 3, 2023, X4 Pharmaceuticals has raised a total of $542.9M (USD).

How many employees does X4 Pharmaceuticals have?

X4 Pharmaceuticals has 72 employees as of Feb 6, 2024.

X4 Pharmaceuticals - Classification

Ownership
  • Public
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Therapeutics
Tags
  • SaaS
Unique IDs
  • ein: 273181608
  • secCik: 0001501697
  • ticker: XFOR
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 2836Biological Products, Except Diagnostic Substances
  • 2800Chemicals And Allied Products
  • 2830Drugs
ISIC
  • 2100Manufacture of pharmaceuticals, medicinal chemical and botanical products
Show 16 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325414Biological Product (except Diagnostic) Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 4000Railroad Transportation
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research